A report card published by the National Organization for Rare Disorders issued grades to each state for 7 categories of rare disease policies.
A report card published by the National Organization for Rare Disorders (NORD) issued grades to each state for 7 categories of rare disease policies. It indicates that progress in these areas has been slow, with many states offering inadequate policy solutions to reduce the burden of illness for these patients.
NORD, an advocacy group representing the 30 million Americans living with rare diseases, first issued a state-by-state policy report last year that “called attention to the lack of policies to ensure access to care for rare disease patients in many states.” The policies examined in that report were prescription drug co-insurance, medical foods access, newborn screening, and Medicaid eligibility. The newly released 2016 report includes 3 additional policy categories: biosimilar prescriber communication, step therapy protection, and state rare disease councils. The format of grading each state from A to F in each of these 7 categories is also new to this year’s report.
The improvement from 2015 to 2016 was minimal. No states expanded Medicaid eligibility for residents or passed new laws to protect patients from high out-of-pocket costs, and very few added new disorders to their newborn screening programs. The report pointed to some positive findings, such as the new bills introduced in several states or the work of advocates to spread awareness of rare diseases.
For some categories, a wide range of grades were seen across the nation. After analysis of coverage and access to medical foods, 29 states were awarded an A or B, 8 states received a C or D, and 13 states failed. All states got an A for screening newborns for a list of core conditions, but less than half scored an A or B for their coverage of secondary condition screening. Just 9 states earned an A or B for their patient protections around the use of step therapy, which according to NORD “can delay appropriate treatment,” while 3 scored a D and the rest failed.
Other categories had a more polarized distribution of grades across states, which “either scored highly or poorly with no real middle ground.” For prescription drug cost sharing, just 9 states received an A or B while the remaining 41 states earned an F. With no significant changes from last year, 32 states scored an A or B on Medicaid expansion, while the rest scored a D or an F. Sufficient laws regarding communication among prescribers of biosimilars were adopted by 30 states, while all but 1 of the remaining states failed due to their lack of such policies. Finally, just 4 states have implemented a rare disease advisory council.
While some of these grades may seem disheartening, the NORD report emphasized that some areas could potentially improve in 2017 through new legislative efforts, including proposed laws to ensure biosimilar prescriber communication and the creation of rare disease advisory councils. Raising awareness of these policy deficiencies is essential to enacting change, according to the press statement that accompanied the report’s release.
“The ultimate purpose of this report is to educate and empower advocates to effect change in their state,” Tim Boyd, associate director of state policy at NORD,said in the statement. “Our team is committed to working with advocates and legislators until ideal policies are achieved in all 50 states and the District of Columbia.”
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen